Research programme: abuse-deterrent therapeutics - Charleston Laboratories
Latest Information Update: 28 Sep 2022
Price :
$50 *
At a glance
- Originator Charleston Laboratories
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Pain in USA
- 08 Aug 2018 Preclinical trials in Pain in USA (unspecified route) (Charleston Laboratories pipeline, August 2018)